By Emmanuel Bobby
The world’s largest public funder of biomedical research is entering a period of uncertainty, with the National Institutes of Health (NIH) facing an unprecedented leadership vacuum that could allow the Trump administration to significantly reshape the agency’s direction.
Despite withstanding repeated attempts by the administration to slash its budget and restructure its grant system, NIH now finds itself vulnerable in another way: a rapidly growing number of vacant top leadership positions. Of the 27 institutes and centers that make up the agency, 16 lacked permanent directors as of Friday, after the latest departure was announced in an internal staff email from NIH Director Jay Bhattacharya. The email confirmed that Dr. Lindsey Criswell would step down as director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, effective immediately.
Nearly all of the vacant director positions have opened during President Donald Trump’s second term, resulting from a mix of terminations, resignations, and retirements. Acting directors are currently filling the gaps, but experts say the scale and speed of the turnover is highly unusual.
“It’s like going to battle with half your generals in place,” said Dr. Elias Zerhouni, who led NIH from 2002 to 2008. “I don’t think it’s precedented to have so many vacancies so fast.”
Powerful Roles with Major Influence
NIH institute directors are among the most influential figures in global biomedical research. They oversee multibillion-dollar budgets and help determine how federal research funding is allocated across critical health priorities, including Alzheimer’s disease, diabetes, heart disease, and cancer. Directors are typically nominated by the NIH director and approved by the secretary of health and human services.
One of the most prominent past directors was Dr. Anthony Fauci, who led the National Institute of Allergy and Infectious Diseases from 1984 to 2022 and played a central role in the U.S. response to HIV/AIDS and Covid-19.
The vacancies come at a pivotal moment. Judges recently blocked an administration effort to cap federal funding for research overhead costs, and Congress rejected a proposal to slash NIH’s budget by 40% and consolidate its institutes. Instead, lawmakers approved a modest funding increase for fiscal year 2026.
For much of its 139-year history, NIH has been seen as a largely nonpartisan engine of scientific progress, supporting breakthroughs such as HIV treatments, Covid vaccines, and major cancer therapies. However, current and former staffers say they fear the agency could become increasingly politicized, depending on who is appointed to fill the vacant leadership posts.
“I’m not confident that their appointments will be with the institute’s mission in mind,” said Shiv Prasad, a scientific review officer at NIH. “I think you’re just there to be compliant with whatever the HHS secretary wants done.”
The Department of Health and Human Services pushed back on those concerns. Spokesperson Andrew Nixon said the agency is committed to appointing highly qualified leaders and strengthening scientific rigor, accountability, and evidence-based research focused on public health needs.
Rising Turmoil Across Public Health Agencies
Leadership instability has not been limited to NIH. Similar upheaval has unfolded across other federal public health institutions, particularly the Centers for Disease Control and Prevention (CDC). Health Secretary Robert F. Kennedy Jr. dismissed CDC Director Susan Monarez just weeks into her tenure, prompting resignations among senior officials and controversy over vaccine guidance changes.
Several NIH staffers say they have witnessed comparable tensions. Dr. Jeanne Marrazzo, who led NIAID from 2023 to 2025, said the agency increasingly mirrored the political dynamics seen at the CDC. She was placed on administrative leave and later fired, a move she believes was tied to her defense of vaccines and opposition to research cancellations. She has filed a whistleblower complaint and lawsuit seeking reinstatement.
Of the NIH directors who have left their posts, some retired, others were fired or placed on leave, and several contracts were not renewed. Many employees believe some removals were ideologically driven, particularly as the administration has signaled interest in investigating vaccine injuries, autism causes, and reshaping federal grant priorities to align with national policy goals.
A Shift in Hiring and Growing Concerns
Traditionally, search committees identify candidates for director positions, but Bhattacharya recently said the agency has altered the process to speed up appointments. Instead of formal committees, NIH is now consulting external partners and internal scientists informally to select new leaders.
Some recent leadership changes have raised eyebrows. At the National Institute of Environmental Health Sciences, Richard Woychik was reassigned and replaced by Kyle Walsh, whose research background differs from the institute’s traditional focus. At the National Institute of Neurological Disorders and Stroke, Dr. Walter Koroshetz’s contract was not renewed despite praise for his performance, prompting concerns from neuroscience organizations about continuity in Alzheimer’s research.
Not all appointments have been controversial. The selection of Dr. Anthony Letai to lead the National Cancer Institute was widely seen as a science-driven decision.
Uncertain Future for U.S. Biomedical Research
Experts warn that prolonged leadership instability could undermine the United States’ global competitiveness in biomedical research. Zerhouni described NIH as a cornerstone of national security and scientific innovation, cautioning that ongoing disruptions could weaken the country’s scientific leadership and ability to attract top talent.
With more than half of NIH’s institutes operating without permanent directors, the agency stands at a crossroads—facing the potential for significant transformation, increased politicization, and long-term consequences for global health research.
If you want, I can make this even longer, more analytical, or convert it into a newspaper-style report with subheadings and quotes highlighted.
Original article
Comments